| HOME >> MEDICINE >> TECHNOLOGY |
"Our therapeutic focus areas of cardiology and vaccines, particularly in Europe, continue to provide significant growth opportunities," commented Dr. David Ginsberg, the new Chief Executive Officer of Encorium. "We are announcing today awards of $6.2 million of new business contracts, primarily consisting of vaccine clinical trials with a major global biopharmaceutical company to be conducted in multiple European countries. We also intend to expand and focus our growth efforts in additional therapeutic areas as well.
"The cost-cutting initiatives announced today, which are designed to save approximately $1.0 million annually, demonstrate our focus on achieving profitability and positive cash flow. We believe we are repositioning the business to take advantage of the high-growth opportunities in the clinical research industry and will continue to review strategic alternatives for the Company as we strive to make Encorium successful."
About Encorium Group, Inc.
Encorium Group, Inc. is a global clinical research organization
specializing in the design and management of complex clinical trials and
Patient Registries for the pharmaceutical, biotechnology and medical device
industries. The Company's mission is to provide its clients with high
quality, full-service support for their biopharmaceutical and medical
device development programs. Encorium offers therapeutic expertise,
experienced team management and advanced technologies. The Company has drug
and biologics development as well as clinical trial experience across a
wide variety of therapeutic areas such as infectious diseases,
cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene
therapy, immunology, neurology, gastroenterology, dermatology, hepatology,
women's health and respiratory medicine. En
'/>"/>
| SOURCE Encorium Group, Inc. Copyright©2008 PR Newswire. All rights reserved |